The facility, set up for the manufacture of betalactam antibiotics, has a built-up area of 4,200 sq mt.
It will have a capacity to produce 12 million vials annually on a single shift basis. The lyophilisation facility was inaugurated by President A P J Abdul Kalam.
The product range includes high-end betalactams such as Tazobactum+Piperacillin, Aztreonam and Ampicillin+Sulbactam injections, which are life-saving antibiotics used in the treatment of a wide variety of infections.
The Tazobactum and Piperacillin active pharmaceutical ingredients, which, at present, are manufactured at Orchid's Aurangabed API plant, will be dissolved into Tazobactum and Piperacillin mixture and lyophilised in vials as dry powder injections at the new facility under sterile conditions.
Lyophilisation is a process by which the product is freeze-dried through a series of unique processes to remove moisture from it without affecting its biological, chemical, and structured properties while maintaining product purity and integrity.
Rao said the new sterile betalactam dosage form facility was the most advanced sterile pharmaceutical manufacturing technology, comparable to the best in the world.
